RAMSAY SANTE : Final annual results as of 30 June 2026

For FY2026 ended June 30, Ramsay Santé revenue rose 3.3% to €5.38bn and EBITDA increased 2.6% to €637.7m, while attributable net loss narrowed to €48.3m from €54.1m. Operating cash flow fell €169m to €524.7m, mainly as working capital normalized; pre-IFRS16 net leverage remained 4.7x. The company completed a €1.75bn senior debt refinancing extending maturities to 2033 and set FY2029 ambitions of about 3% annual revenue growth and net debt/EBITDA below 4.0x, alongside its Connecting Care 2030 strategy.

Analysis

The earnings quality is better than the headline growth suggests, but the equity remains a deleveraging story. Working-capital normalization explains much of the cash-flow decline, so it should not be extrapolated; however, stable 4.7x pre-IFRS leverage despite higher EBITDA shows that organic growth alone is not yet reducing balance-sheet risk. The <4.0x FY2029 target therefore depends on sustained earnings growth and cash conversion, not just the announced roadmap. Refinancing extends maturities but the floating-rate TLB leaves financing costs and equity sensitivity exposed while leverage is high.

Near term (days to 1–3 months), the proposed RHC distribution and ASX CDI route may broaden the shareholder base, but can also create technical selling as recipients monetize a newly received, unfamiliar listing. Treat any post-distribution weakness as a potential entry window only after supply stabilizes; the transaction remains subject to approvals. The new St. Göran contract supports Nordic growth, but reported Nordic growth includes a material FX tailwind, while France faces constrained public reimbursement, unfavorable day-patient mix, and imaging price cuts. These limit confidence that volume growth converts to margin expansion.

Over 6–18 months, the key upside is productivity and contract economics translating into cash deleveraging; the key downside is wage/procurement inflation or weaker reimbursement consuming those gains. The press-release targets are management ambitions, not verified run-rate improvements. Contrarian angle: the cash-flow fall may look alarming but is largely a working-capital comparison; conversely, stable reported margin should not be read as a clear operating inflection. Falsify the constructive view if leverage rises above 4.7x, cash conversion remains weak after working capital normalizes, or France/Nordics margins deteriorate.

Key Decisions for Investors

• Do not chase the modestly positive operating result as a clean rerating catalyst. Keep GDS exposure measured until quarterly cash conversion and leverage show a sustained downward trend.
• Set an alert for post-RHC-distribution selling pressure: consider scaling into GDS only after the new free float is absorbed and the distribution/ASX CDI approvals and timetable are clear. A delayed or materially altered transaction invalidates this technical-entry setup.
• Credit: the refinancing removes near-term maturity uncertainty, but does not eliminate high leverage or floating-rate exposure. Consider GDS senior debt only if secondary-market pricing offers compensation versus the new E+350bp primary terms; verify current spread, documentation and interest-rate sensitivity first.
• Monitor French like-for-like growth and EBITDA/cash conversion over the next 1–3 quarters. A renewed leverage increase, persistent working-capital outflow, or evidence that staffing and procurement inflation is outrunning reimbursement would negate the constructive thesis.